What researchers published on Chronic myeloid leukaemia
904 papers, newest first.
Showing 40 of 904
Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia.Haematologica
Is Bone Marrow Examination Still Required at Diagnosis of Typical Chronic-Phase Chronic Myeloid Leukemia? Evidence From Paired Peripheral Blood and Bone Marrow Cytogenetics.American journal of hematology
ReviewPredictive factors for TKI discontinuation eligibility and treatment-free remission in chronic myeloid leukemia.International journal of hematology
Pharmacological SOS1 inhibitor BI-3406 synergizes with BCR::ABL1 TKIs reducing leukemia stem cells and overcoming imatinib resistance in CML.Cell death & disease
Differential regulation of PRSS57 by tyrosine kinase inhibitors and ATRA in myeloid leukaemia cells: an in vitro study.Journal of applied genetics
Investigation of selected MiRNA as potential biomarker in chronic myeloid leukemia patients.Medicine and pharmacy reports
Capillary dried plasma microsampling: A novel approach for therapeutic drug monitoring of tyrosine kinase inhibitors in chronic myeloid leukemia patients by UPLC-MS/MS.Journal of pharmaceutical and biomedical analysis
Correction: Target inhibition of CBP induced cell senescence in BCR-ABL- T315I mutant chronic myeloid leukemia.Frontiers in oncology
Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: long-term efficacy and endocrine analysis.Blood advances
Case reportProlonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms.Annals of hematology
Aptamers in cancer research: Focus on leukemia.Chinese medical journal
A novel SLTM::RUNX1 acquired during CML progression and the clinical significance of concurrent BCR::ABL1 and RUNX1 rearrangements in Ph-positive leukemia.Cancer genetics
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.Leukemia
Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors.Journal of medical virology
ReviewEmerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.International journal of hematology
Case reportChronic Myeloid Leukemia Progressing to Early T-Cell Precursor Lymphoblastic Blast Phase Following Treatment Default: An Integrated Morphologic, Immunophenotypic, Cytogenetic, and Molecular Case Report.Cureus
ANGPT1-based targeted drug screening: Identification of Tasosartan and its activity against tyrosine kinase inhibitor resistance in chronic myeloid leukemia.The Journal of international medical research
Assessment of Interpatient and Intrapatient Variability of Dasatinib and Imatinib Concentrations in Patients With Chronic Myeloid Leukemia via Volumetric Absorptive Microsampling at Home.Therapeutic drug monitoring
Case reportBone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.Cureus
Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group.Annals of hematology
Review[Treatment strategies for chronic-phase chronic myeloid leukemia in 2026].[Rinsho ketsueki] The Japanese journal of clinical hematology
ReviewChronic Myeloid Leukemia Beyond BCR::ABL1 Inhibition: Resistance Mechanisms and Emerging Therapeutic Modalities.Pharmaceuticals (Basel, Switzerland)
Leukostasis-related retinopathy as the initial presentation of chronic-phase chronic myeloid leukaemia.BMJ case reports
Case reportPeritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum.The Medical journal of Australia
Predictive Value of the Zhang Scoring System for Imatinib Failure in Chronic Myeloid Leukemia: A Comparative Analysis with Established Prognostic Models.Turkish journal of haematology : official journal of Turkish Society of Haematology
Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?Journal of hematology & oncology
Imatinib Resistance in Chronic Myeloid Leukemia Is Associated with Distinct Metabolic, Oxidative, and Autophagic Adaptations in K562-Derived Cell Sublines.Biomedicines
Profiling Tyrosine Kinase Inhibitor-Specific Signatures of Homocysteine Metabolism and Mineral Homeostasis in Chronic Myeloid Leukemia.Asian Pacific journal of cancer prevention : APJCP
scDRP: disentangled representation learning for predicting single-cell responses to perturbations and estimating individual treatment effects.Briefings in bioinformatics
LEDGF/p75 Mediates Chemoresistance in Leukemia in a Context Dependent Manner.Cells
Asciminib After Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia: A Multicenter Real-World Experience.Clinical lymphoma, myeloma & leukemia
Observational studyImpact of BCL3 Expression and Clinical-Hematologic Risk Factors on Early Molecular Response, Reticulin Fibrosis, and Survival Outcomes in Chronic Myeloid Leukemia: A Prognostic Cohort Study.La Clinica terapeutica
Case reportSequential Philadelphia-Positive Pre-B Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia With Distinct BCR::ABL1 Fusion Transcripts.Cancer reports (Hoboken, N.J.)
Correction to: Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Annals of hematology
Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.American journal of cancer research
Correction: Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo.Frontiers in pharmacology
Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia.Leukemia research
ReviewTwenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting.Clinical lymphoma, myeloma & leukemia
ReviewCurrent perspectives on high-risk genomic profiles in chronic myeloid leukemia: from bench to clinical practice.International journal of hematology